Argenx SE
ARGX
Classifica tra le azioni
#470
argenx SE, a biotechnology company established in Amsterdam, the Netherlands,... argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx's business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. A specific collaboration with Genmab A/S focuses on the discovery, development, and commercialization of novel therapeutic antibodies for immunology and oncology applications. Additionally, argenx has a strategic collaboration with IQVIA Holdings Inc. for the provision of safety systems and related services.
Prezzo delle azioni
$823.02
Ultima sincronizzazione: 2026-10-19
Capitalizzazione di mercato
$51.58B
Variazione (1 giorno)
0.47%
Variazione (1 anno)
-3.11%
Paese
NL
Scambia Argenx SE (ARGX)
Categoria
Healthcare
Utile per Argenx SE (ARGX)
Utile nel Jun 2026 TTM: $1.95B
Secondo gli ultimi rapporti finanziari di Argenx SE, gli utili attuali della società sono $1.95B. Nel 2023, la società ha registrato un utile di $-304.50M, un aumento rispetto a agli utili del 2022, che erano di $-729.31M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Argenx SE dal 2011 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $1.95B | 2,190.03% |
| 2024 | $85.18M | -127.97% |
| 2023 | $-304.50M | -58.25% |
| 2022 | $-729.31M | 82.45% |
| 2021 | $-399.74M | -45.78% |
| 2020 | $-737.24M | 273.52% |
| 2019 | $-197.38M | 128.03% |
| 2018 | $-86.56M | 118.82% |
| 2017 | $-39.56M | 67.25% |
| 2016 | $-23.65M | 30.12% |
| 2015 | $-18.18M | 19.79% |
| 2014 | $-15.18M | 30.35% |
| 2013 | $-11.64M | -31.19% |
| 2012 | $-16.92M | 191.01% |
| 2011 | $-5.81M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $5.27B | 170.42% |
US
|
|
| $-3.09B | -258.25% |
US
|
|
| $-4.02B | -305.89% |
AU
|
|
| - | - |
CH
|
|
| $3.01B | 54.09% |
BE
|
